Replimune (REPL) Gains from Investment Securities (2017 - 2018)
Replimune (REPL) reported Gains from Investment Securities of $2000.0 for Q3 2018, down 99.65% on a YoY basis from $578000.0 in Q3 2017, and down 99.96% sequentially from $5.4 million in Q2 2018.
Replimune (REPL) Gains from Investment Securities (2017 - 2018) Analysis & Trends
Replimune (REPL) has 2 years of Gains from Investment Securities data on file, last reported at $2000.0 in Q3 2018.
- For the quarter ending Q3 2018, Gains from Investment Securities fell 99.65% year-over-year to $2000.0; the trailing twelve-month figure through Jun 2019 stood at $2000.0 (down 99.97% YoY), and the FY2019 full-year result was $5.5 million, up 460.91% from the prior year.
- Gains from Investment Securities fell to $2000.0 in Q3 2018, from $5.4 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $5.4 million in Q2 2018 to a low of $2000.0 in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Replimune | 970.73 Mn | 970.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 2,000.00 |
| Sep 30, 2018 | 2,000.00 |
| Jun 30, 2018 | 5.45 Mn |
| Jun 30, 2018 | 5.45 Mn |
| Mar 31, 2018 | 7,000.00 |
| Mar 31, 2018 | 7,000.00 |
| Dec 31, 2017 | 387,000.00 |
| Dec 31, 2017 | 387,000.00 |
| Sep 30, 2017 | 578,000.00 |
| Sep 30, 2017 | 578,000.00 |